BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RVX-208: Completed Phase IIb enrollment

Resverlogix completed enrollment of 176 patients receiving statin therapy in the double-blind, placebo-controlled, South African Phase IIb SUSTAIN trial evaluating 100 mg oral RVX-208 twice...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >